Yves Luder
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Managing transient immune complex reactions in patients with paroxysmal nocturnal hemoglobinuria: clinical observations from the COMMODORE 1 and 2 studies.
Journal: Therapeutic advances in hematology
Published: February 11, 2025
Treatment failure in giant cell arteritis.
Journal: Annals of the rheumatic diseases
Published: March 12, 2021
Tocilizumab vs placebo for the treatment of giant cell arteritis with polymyalgia rheumatica symptoms, cranial symptoms or both in a randomized trial.
Journal: Seminars in arthritis and rheumatism
Published: January 08, 2021
Effect of disease duration and other characteristics on efficacy outcomes in clinical trials of tocilizumab for rheumatoid arthritis.
Journal: Rheumatology (Oxford, England)
Published: March 04, 2020
Effect on efficacy and safety trial outcomes of also enrolling patients on ongoing glucocorticoid therapy in rheumatoid arthritis clinical trials of tocilizumab or adalimumab or methotrexate monotherapy.
Journal: Annals of the rheumatic diseases
Published: November 19, 2019
Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naïve patients with rheumatoid arthritis.
Journal: Seminars in arthritis and rheumatism
Published: March 22, 2019
Tocilizumab Patterns of Use, Effectiveness, and Safety in Patients with Rheumatoid Arthritis: Final Results from a Set of Multi-National Non-Interventional Studies.
Journal: Rheumatology and therapy
Published: January 16, 2019
Long-term safety and effectiveness of tocilizumab in patients with rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: an open-label study close to clinical practice.
Journal: Clinical rheumatology
Published: December 21, 2018
Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration.
Journal: Annals of the rheumatic diseases
Published: December 14, 2017
Showing 1-9 of 9
Last Updated: 09/26/2026